The KO Cancer Act would provide additional funding for the National Cancer Institute to conduct or support cancer research. For each fiscal year from 2026 through 2030, it would appropriate an amount equal to 25% of the total amount appropriated to the institute for fiscal year 2022. The bill would also require a study of cancer drug shortages and a report to Congress with recommendations within one year of enactment. The bill was introduced and referred to House committees.
The bill focuses on cancer research and the causes of cancer drug shortages. It does not describe a direct service or benefit for individuals.
The bill sets funding using a formula based on the National Cancer Institute’s fiscal year 2022 appropriation. It does not state a specific dollar amount. The funding would be in addition to other amounts available to the institute and would remain available until spent.
The bill’s findings say that cancer research can lead to improved treatments and that increased research funding could help address cancer deaths and effects on patients.
No publicly available information.